A. Swat

583 citations
6 papers · 354 · 1 hit paper · h-index 4

Impact in

  • Oncology top 10%
    • Cancer Immunotherapy and Biomarkers
    • HER2/EGFR in Cancer Research
    • CAR-T cell therapy research
    • Cancer Cells and Metastasis
    • Cancer Genomics and Diagnostics
    • Breast Cancer Treatment Studies

Papers in

    • Cancer Immunotherapy and Biomarkers 4
    • Cancer Treatment and Pharmacology 3
    • HER2/EGFR in Cancer Research 2
    • CAR-T cell therapy research 1
    • Advanced Breast Cancer Therapies 4
    • Prostate Cancer Treatment and Research 2

A. Swat

6 papers receiving 349 citations

Hit Papers

First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis 2021 · 293 citations
2930+1+3Years since publication50100150200250

Peers

A. Swat
Comparison fields: 5 of 39
  • Oncology 305
  • Cancer Research 112
  • Immunology 89
  • Pulmonary and Respiratory Medicine 135
  • Radiology, Nuclear Medicine and Imaging 20
Replace P. Schmid with:
P. Schmid United Kingdom
M.C. Liu United States
Miao Ruan China
Aleksandra Łacko Poland
C. Zamagni Italy
W Kitonyi Grace Canada
G. Scott Chandler United States
R. Dent Spain
Silvia Esposito Italy
M.A. Vicente Conesa Spain
A. Swat relative to P. Schmid United Kingdom P. Schmid's profile →
Citations per field
00.5×1.5×2.5×
P. Schmid · 1×
Citations per year

Countries citing papers authored by A. Swat

Since Specialization
Citations

This map shows the geographic impact of A. Swat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Swat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Swat more than expected).

Fields of papers citing papers by A. Swat

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Swat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Swat. The network helps show where A. Swat may publish in the future.

Co-authors

The 25 scholars most cited alongside A. Swat, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with A. Swat Line = papers co-authored together A. Swat links everyone, so they are left out of the graph.

All Works

6 of 6 papers shown
#Work
1
First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis
Hit paper breakdown →
2021293
2 202044
3 20208
4 20243
5 20173
6 20163

About A. Swat

A. Swat is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Infectious Diseases and Organic Chemistry, having authored 6 papers that have together received 354 indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (4 papers), Cancer Immunotherapy and Biomarkers (4 papers), Cancer Treatment and Pharmacology (3 papers), Prostate Cancer Treatment and Research (2 papers), Breast Cancer Treatment Studies (2 papers), HER2/EGFR in Cancer Research (2 papers) and CAR-T cell therapy research (1 paper). The work is most often cited by research in Oncology (305 citations), Cancer Research (112 citations), Immunology (89 citations), Pulmonary and Respiratory Medicine (135 citations) and Radiology, Nuclear Medicine and Imaging (20 citations). A. Swat has collaborated with scholars based in Switzerland, United States and Germany. Frequent co-authors include Sylvia Adams, Andreas Schneeweiß, Volkmar Henschel, Leisha A. Emens, Véronique Dièras, Carlos H. Barrios, Sherene Loi, Hiroji Iwata, Manika Kaul and Shilpen Patel. Their work appears in journals such as Annals of Oncology, Cancer Research and ESMO Open.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact